Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced it will host a conference call and live webcast on Tuesday, July 23, 2024, at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution. The event will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Interested individuals can register for telephone participation, and upon registration, will receive confirmation details including a unique passcode and registrant ID. A replay of the event will be available on Kiniksa's website within approximately 48 hours after the event.
Details
News Market Reaction – KNSA
The recorded move for KNSA in the trading session of this news was -4.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
Every Second Counts! ®
Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.